Xspray Pharma
25.00 SEK
+3.95 %
Less than 1K followers
XSPRAY
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+3.95 %
-7.24 %
-1.88 %
-18.26 %
-28.88 %
-15.71 %
-36.81 %
-70.61 %
-14.88 %
Xspray Pharma is a pharmaceutical company with several product candidates in clinical development that uses the patented HyNap technology to create improved versions of marketed protein kinase inhibitors. The drug candidate Dasynoc® is an amorphous form of dasatinib and is undergoing FDA review for market approval. Xspray Pharma's product portfolio also includes XS003-nilotinib, XS008-axitinib and XS025-cabozantinib.
Read moreMarket cap
1.19B SEK
Turnover
6.05M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/8
2026
Interim report Q2'26
5/11
2026
Interim report Q3'26
11/2
2027
Annual report '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026
Finansinspektionen: Flaggningsmeddelande i XSpray Pharma AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools